sodium fluoride and Menopause studies

Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.

Research Excerpts

Excerpt	Relevance	Reference
"Thirty seven female patients with osteoporosis underwent iliac bone biopsy after 10 to 23 months of continuous or discontinuous treatment with sodium fluoride, calcium, and vitamin D."	7.67	[Microradiographic study of iliac bone biopsies taken after treatment of postmenopausal osteoporosis with sodium fluoride. Histomorphometric correlations]. ( Duriez, J; Duriez, R; Flautre, B, 1989)
"Calcium and phosphorus balances and 47Ca turnover studies were performed before and after 12-27 months of daily treatment with sodium fluoride (60 mg), calcium (30-45 mmol), phosphate (29-44 mmol), and vitamin D2 (18,000 IU) in 20 postmenopausal women with spinal crush fracture osteoporosis."	7.67	The effects of sodium fluoride, calcium phosphate, and vitamin D2 for one to two years on calcium and phosphorus metabolism in postmenopausal women with spinal crush fracture osteoporosis. ( Charles, P; Jensen, FT; Mosekilde, L, 1985)
"Thirty seven female patients with osteoporosis underwent iliac bone biopsy after 10 to 23 months of continuous or discontinuous treatment with sodium fluoride, calcium, and vitamin D."	3.67	[Microradiographic study of iliac bone biopsies taken after treatment of postmenopausal osteoporosis with sodium fluoride. Histomorphometric correlations]. ( Duriez, J; Duriez, R; Flautre, B, 1989)
"Forty-one women with idiopathic postmenopausal osteoporosis have been followed for 2 years after initiation of sodium fluoride at 40-50 mg/day, given together with a daily calcium supplement of 1 gram and vitamin D2, at 50,000 IU weekly."	3.67	The effect of fluoride on bone histology in postmenopausal osteoporosis depends on adequate fluoride absorption and retention. ( Bayley, TA; Budden, FH; Goodwin, S; Harrison, JE; Josse, RG; Kandel, R; Murray, TM; Strauss, AL; Sturtridge, WC; Vieth, R, 1988)
"The benefit of sodium fluoride (NaF) in the therapy of osteoporosis is still controversial."	3.67	Long-term fluoride therapy of postmenopausal osteoporosis. ( Dambacher, MA; Ittner, J; Ruegsegger, P, 1986)
"Calcium and phosphorus balances and 47Ca turnover studies were performed before and after 12-27 months of daily treatment with sodium fluoride (60 mg), calcium (30-45 mmol), phosphate (29-44 mmol), and vitamin D2 (18,000 IU) in 20 postmenopausal women with spinal crush fracture osteoporosis."	3.67	The effects of sodium fluoride, calcium phosphate, and vitamin D2 for one to two years on calcium and phosphorus metabolism in postmenopausal women with spinal crush fracture osteoporosis. ( Charles, P; Jensen, FT; Mosekilde, L, 1985)
"Risk fractures for osteoporosis are numerous."	2.39	Osteoporotic fractures: background and prevention strategies. ( Wark, JD, 1996)
"Osteoporosis is a skeletal condition in which there is a loss of bone mass, evident radiographically by diffuse rarefaction or clinically by overt fractures."	2.37	Osteoporosis. ( Lane, JM; Vigorita, VJ, 1984)
"Osteoporosis is a major public health problem, particularly for the postmenopausal woman."	2.37	Postmenopausal osteoporosis. ( Lindsay, R; Silverberg, SJ, 1987)
"Osteoporosis is a serious metabolic bone disorder that results in fractures of the wrist, hip and vertebrae."	1.27	Osteoporosis: significance, risk factors and treatment. ( Coralli, CH; Raisz, LG; Wood, CL, 1986)
"Osteoporosis is the most common bone disorder in the United States."	1.27	Osteoporosis. ( Davies, R; Saha, S, 1985)
""Osteoporosis" is no disease by itself, but solely an anatomically equal result of various etiologic and pathogenetic influences on the bone structure or parts of same."	1.26	[Principles in the therapy of osteoporosis. 2. Therapy]. ( Jesserer, H, 1977)

Research

Studies (36)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Changes in Femoral Neck BMD +/- Treatment With Alendronate

Timeframe	Studies, this research(%)	All Research%
pre-1990	34 (94.44)	18.7374
1990's	2 (5.56)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Christiansen, C	2
Mazess, RB	1
Transbøl, I	1
Jensen, GF	1
Riggs, BL	1
Seeman, E	2
Hodgson, SF	1
Taves, DR	1
O'Fallon, WM	1
Lane, JM	2
Vigorita, VJ	2
Dixon, AS	1
Grove, O	1
Halver, B	1
Chesnut, CH	3
Briançon, D	1
Meunier, PJ	2
Milhaud, G	1
Gallagher, C	2
Reeve, J	1
Chesnut, C	1
Parfitt, A	1
Harrison, JE	2
McNeill, KG	1
Sturtridge, WC	2
Bayley, TA	2
Murray, TM	2
Williams, C	1
Tam, C	1
Fornasier, V	1
Rico Lenza, H	1
Espinós Pérez, D	1
Lie, H	1
Malde, K	1
Sorteberg, K	1
Hasvold, O	1
Ekren, T	1
Malm, OJ	1
Farley, JR	1
Baylink, DJ	1
Wark, JD	1
Wallach, S	1
Avioli, LV	1
Jesserer, H	1
Duriez, R	1
Flautre, B	1
Duriez, J	2
Hedlund, LR	1
Gallagher, JC	1
de Guembecker, W	1
de Guembecker, C	1
Reutter, FW	1
Budden, FH	1
Josse, RG	1
Kandel, R	1
Vieth, R	1
Strauss, AL	1
Goodwin, S	1
Pak, CY	1
Sakhaee, K	1
Parcel, C	1
Peterson, R	1
Zerwekh, JE	1
Lemke, M	1
Britton, F	1
Hsu, MC	1
Adams, B	1
Melick, RA	1
Werntz, JR	1
Healey, JH	1
Silverberg, SJ	1
Lindsay, R	1
Parfitt, AM	1
Coralli, CH	1
Raisz, LG	1
Wood, CL	1
Dambacher, MA	1
Ittner, J	1
Ruegsegger, P	1
Keck, E	1
Krüskemper, HL	1
Charles, P	1
Mosekilde, L	1
Jensen, FT	1
Frame, B	1
McKenna, MJ	1
Power, GR	1
Gay, JD	1
Davies, R	1
Saha, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Changes in Bone Density, Radiographic Texture Analysis and Bone Turnover During Two Years of Antiresorptive Therapy for Postmenopausal Osteoporosis[NCT00145977]		36 participants (Actual)	Interventional	2001-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Percent Change in femoral neck BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24

Changes in Lumbar Spine BMD +/- Treatment With Alendronate

Intervention	Percent Change (Mean)
Alendronate	-4.21
Control	0.04

Percent Change in lumbar spine BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24

Changes in Peripheral Heel BMD +/- Treatment With Alendronate

Intervention	Percent Change (Mean)
Alendronate	5.28
Control	-1.48

Percent Change in peripheral heel BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24

Changes in Radiographic Texture Analysis (RTA) Feature Integrated First Moment of the Power Spectrum (iFMP) From Baseline to Month 24

Intervention	Percent Change (Mean)
Alendronate	1.02
Control	-1.99

To derive a measure of variability and directionality in the first moment of the power spectrum (FMP) in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and FMP is calculated for each segment. We use iFMP (integrated FMP) as a measure of overall special frequency of the radiographic pattern. FMP characterizes spatial frequency in the radiographic pattern and the underlying trabecular structure. This corresponds to the coarseness or fineness of the radiographic texture pattern. A high level of FMP indicates thin and closely spaced trabecular structure. Low FMP indicates widely spaced dark areas usually corresponding to a strong, thick trabecular structure. (NCT00145977)
Timeframe: Baseline to Month 24

Changes in Radiographic Texture Analysis (RTA) Feature Standard Deviation of Root Mean Square (sdRMS) From Baseline to Month 24

Intervention	Percent Change (Mean)
Alendronate	0.09
Control	1.04

"Root Mean Square (RMS) is a measure of the variability in the radiographic texture pattern, the relative difference in the contrast between light and dark areas is expressed in a grayscale level. In practical terms, a bone image with a washed-out appearance due to loss of trabecular structure such as that seen in osteoporosis, will have a low value for RMS because there will be relatively little contrast between lighter and darker areas of the image. An image of a bone with strong trabecular structure will have a high RMS value because the contrast between the lighter and darker areas of the image will be greater.~To derive a measure of variability in the RMS in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and RMS is calculated for each segment. We use sdRMS (standard deviation of the RMS across the segments) as a measure of the direction dependence (anisotropy) of the trabeculae in the bone image." (NCT00145977)
Timeframe: Baseline to Month 24

Changes in Radiographic Texture Analysis (RTA) Integrated Root Mean Square (iRMS) From Baseline to Month 24

Intervention	Percent Change (Mean)
Alendronate	6.85
Control	1.08

"Root Mean Square (RMS) is a measure of the variability in the radiographic texture pattern, the relative difference in the contrast between light and dark areas is expressed in a grayscale level. In practical terms, a bone image with a washed-out appearance due to loss of trabecular structure such as that seen in osteoporosis, will have a low value for RMS because there will be relatively little contrast between lighter and darker areas of the image. An image of a bone with strong trabecular structure will have a high RMS value because the contrast between the lighter and darker areas of the image will be greater.~To derive a measure of variability in the RMS in the region of interest in the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and RMS is calculated for each segment. The iRMS (integrated RMS) roughly corresponds to RMS averaged across all 24 angular sectors" (NCT00145977)
Timeframe: Baseline to Month 24

Changes in Radiographic Texture Analysis (RTA) Minimum First Moment of the Power Spectrum (minFMP) From Baseline to Month 24

Intervention	Percent Change (Mean)
Alendronate	-3.70
Control	-0.53

To derive a measure of variability and directionality in the first moment of the power spectrum (FMP) in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals and FMP is calculated for each segment. We use minFMP (minimum FMP) to represent the lowest value of FMP across the 24 angular sectors corresponding to the special frequency in the most washed-out direction. FMP characterizes spatial frequency in the radiographic pattern and the underlying trabecular structure. This corresponds to the coarseness or fineness of the radiographic texture pattern. A high level of FMP indicates thin and closely spaced trabecular structure. Low FMP indicates widely spaced dark areas usually corresponding to a strong, thick trabecular structure. (NCT00145977)
Timeframe: Baseline to Month 24

Changes in Radiographic Texture Analysis (RTA) Minkowski Fractal Dimension (MINK) From Baseline to Month 24

Intervention	Percent Change (Mean)
Alendronate	-3.61
Control	-0.18

The Percent Change in Radiographic Texture Analysis (RTA) Minkowski Fractal Dimension (MINK) from Baseline to Month 24 is a description of the similarity of texture of the images at different magnifications. The Minkowski fractal dimension is calculated from the slope of the least -square fitted line relating log volume and log magnification. (NCT00145977)
Timeframe: Baseline to Month 24

Changes in Radiographic Texture Analysis (RTA) Spectral Density Coefficient Beta (BETA) From Baseline to Month 24

Intervention	Percent Change (Mean)
Alendronate	-0.06
Control	0.12

The Percent Change in Radiographic Texture Analysis (RTA) spectral density coefficient beta (BETA) from Baseline to Month 24 is an analysis of spectral density vs. the spacial frequency on a log-log plot. BETA is the coefficient (slope) of this plot. Higher values of beta correspond to rougher (strong bone) and lower values to smoother, higher-frequency texture pattern (washed out bone). (NCT00145977)
Timeframe: Baseline to Month 24

Changes in Total Hip BMD +/- Treatment With Alendronate

Intervention	Percent Change (Mean)
Alendronate	3.09
Control	6.53

Percent Change in total hip BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24

Article	Year
Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. The New England journal of medicine, 1982, Feb-25, Volume: 306, Issue:8 Topics: Aged; Calcium; Clinical Trials as Topic; Drug Therapy, Combination; Estrogens, Conjugated (USP); Fem	1982
Relief of osteoporotic backache with fluoride, calcium, and calciferol. Acta medica Scandinavica, 1981, Volume: 209, Issue:6 Topics: Aged; Back Pain; Calcium; Clinical Trials as Topic; Drug Therapy, Combination; Ergocalciferols; Fema	1981
New drugs for osteoporosis. The Medical letter on drugs and therapeutics, 1996, Jan-05, Volume: 38, Issue:965 Topics: Administration, Intranasal; Aged; Alendronate; Calcitonin; Calcium; Costs and Cost Analysis; Delayed	1996
Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1989, Volume: 4, Issue:2 Topics: Aged; Aged, 80 and over; Calcitriol; Calcium; Drug Therapy, Combination; Female; Hip Fractures; Huma	1989

Article	Year
Factors in response to treatment of early postmenopausal bone loss. Calcified tissue international, 1981, Volume: 33, Issue:6 Topics: Alkaline Phosphatase; Bendroflumethiazide; Bone and Bones; Calcium; Cholecalciferol; Estrogens; Fema	1981
Non-hormonal treatment of osteoporosis. British medical journal (Clinical research ed.), 1983, Mar-26, Volume: 286, Issue:6370 Topics: Adult; Aged; Calcium, Dietary; Female; Humans; Male; Menopause; Osteoporosis; Sodium Fluoride	1983
Treatment of postmenopausal osteoporosis: some current concepts. Scottish medical journal, 1981, Volume: 26, Issue:1 Topics: Aged; Calcitonin; Calcium Carbonate; Clodronic Acid; Ergocalciferols; Estrogens; Female; Humans; Men	1981
[Treatment of postmenopausal osteoporosis with sodium fluoride]. La Revue de medecine interne, 1983, Volume: 4, Issue:2 Topics: Female; Fluorides; Humans; Menopause; Middle Aged; Osteoporosis; Sodium Fluoride	1983
Pathogenesis and treatment of postmenopausal osteoporosis. Calcified tissue international, 1983, Volume: 35, Issue:6 Topics: Aged; Calcitonin; Calcitriol; Female; Fractures, Bone; Hormones; Humans; Malabsorption Syndromes; Me	1983
Treatment of postmenopausal osteoporosis. Comprehensive therapy, 1984, Volume: 10, Issue:7 Topics: Aged; Anabolic Agents; Androgens; Calcitonin; Calcium; Diphosphonates; Estrogens; Female; Humans; Me	1984
Three-year changes in bone mineral mass of postmenopausal osteoporotic patients based on neutron activation analysis of the central third of the skeleton. The Journal of clinical endocrinology and metabolism, 1981, Volume: 52, Issue:4 Topics: Bone and Bones; Calcium; Ergocalciferols; Estrogens; Female; Fluorides; Follow-Up Studies; Humans; M	1981
[Our experience in the treatment of post-menopausal osteoporosis (author's transl)]. Medicina clinica, 1982, Apr-16, Volume: 78, Issue:8 Topics: Adult; Aged; Calcitonin; Calcium; Drug Therapy, Combination; Female; Fluorides; Humans; Menopause; M	1982
Long-term fluoride and calcium therapy of postmenopausal osteoporosis. Journal of the Oslo city hospitals, 1982, Volume: 32, Issue:12 Topics: Aged; Calcium Carbonate; Delayed-Action Preparations; Female; Fluorides; Humans; Menopause; Middle A	1982
Improved method for quantitative determination in serum of alkaline phosphatase of skeletal origin. Clinical chemistry, 1981, Volume: 27, Issue:12 Topics: Alkaline Phosphatase; Bone and Bones; Female; Hot Temperature; Humans; Intestines; Isoenzymes; Liver	1981
Management of osteoporosis. Hospital practice, 1978, Volume: 13, Issue:12 Topics: Aged; Androgens; Calcitonin; Estrogens; Ethnicity; Female; Humans; Male; Menopause; Middle Aged; Ost	1978
What to do with "postmenopausal osteoporosis?". The American journal of medicine, 1978, Volume: 65, Issue:6 Topics: Aged; Androgens; Biopsy; Bone and Bones; Calcium, Dietary; Estrogens; Female; Growth Hormone; Humans	1978
[Principles in the therapy of osteoporosis. 2. Therapy]. Fortschritte der Medizin, 1977, Feb-24, Volume: 95, Issue:8 Topics: Anabolic Agents; Calcium; Cortisone; Estrogens; Female; Growth Hormone; Humans; Male; Menopause; Ost	1977
[Microradiographic study of iliac bone biopsies taken after treatment of postmenopausal osteoporosis with sodium fluoride. Histomorphometric correlations]. Revue du rhumatisme et des maladies osteo-articulaires, 1989, Volume: 56, Issue:5 Topics: Adult; Aged; Biopsy; Calcifediol; Calcium; Female; Fluoride Poisoning; Humans; Ilium; Menopause; Mic	1989
[Treatment of postmenopausal with sodium fluoride. Effect on mineral bone content of the radius]. Revue du rhumatisme et des maladies osteo-articulaires, 1989, Volume: 56, Issue:6 Topics: Aged; Female; Humans; Menopause; Minerals; Osteoporosis; Radionuclide Imaging; Radius; Sodium Fluori	1989
The effect of fluoride on bone histology in postmenopausal osteoporosis depends on adequate fluoride absorption and retention. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1988, Volume: 3, Issue:2 Topics: Biopsy; Bone and Bones; Female; Humans; Intestinal Absorption; Menopause; Middle Aged; Osteoporosis;	1988
Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1986, Volume: 1, Issue:6 Topics: Aged; Aged, 80 and over; Biological Availability; Circadian Rhythm; Delayed-Action Preparations; Fem	1986
Osteoporosis: significance, risk factors and treatment. The Nurse practitioner, 1986, Volume: 11, Issue:9 Topics: Aged; Biomechanical Phenomena; Calcitonin; Calcium; Estrogens; Female; Humans; Menopause; Middle Age	1986
Long-term fluoride therapy of postmenopausal osteoporosis. Bone, 1986, Volume: 7, Issue:3 Topics: Aged; Alkaline Phosphatase; Female; Fractures, Spontaneous; Humans; Menopause; Middle Aged; Osteopor	1986
[Pathogenesis and therapy of osteoporosis in the postmenopausal period]. Der Gynakologe, 1986, Volume: 19, Issue:4 Topics: Bone and Bones; Calcium; Estradiol Congeners; Estrogens; Female; Fractures, Spontaneous; Humans; Men	1986
The effects of sodium fluoride, calcium phosphate, and vitamin D2 for one to two years on calcium and phosphorus metabolism in postmenopausal women with spinal crush fracture osteoporosis. Bone, 1985, Volume: 6, Issue:4 Topics: Aged; Bone and Bones; Bone Resorption; Calcium; Calcium Phosphates; Ergocalciferols; Female; Fractur	1985
Osteoporosis. Postmenopausal or secondary? Hospital practice (Office ed.), 1985, Oct-30, Volume: 20, Issue:10A Topics: Adult; Biopsy; Bone and Bones; Bone Resorption; Estrogens; Female; Humans; Menopause; Middle Aged; O	1985
Sodium fluoride in the treatment of osteoporosis. Clinical and investigative medicine. Medecine clinique et experimentale, 1986, Volume: 9, Issue:1 Topics: Calcium; Female; Fractures, Bone; Humans; Menopause; Osteoporosis; Sodium Fluoride	1986
[The osteoporosis disease in menopausal women. Physiopathology and therapeutic impact]. Revue francaise de gynecologie et d'obstetrique, 1985, Volume: 80, Issue:4 Topics: Calcium; Estrogens; Exercise Therapy; Female; Humans; Menopause; Middle Aged; Osteoporosis; Radius F	1985
Osteoporosis. American family physician, 1985, Volume: 32, Issue:5 Topics: Aged; Bone and Bones; Calcium; Estrogens; Female; Forearm Injuries; Fractures, Bone; Hip Fractures;	1985

sodium fluoride and Menopause